surmount-1 trial tirzepatide weight loss non-diabetic obesity For the first time, and semaglutide were put in Tirzepatide for the Maintenance of – Surmount Press Briefing #ADA2022

So if someone is taking a GLP-1 agonist for diabetes or weight management and they have co-occurring substance use issues, they may be helped by these medications. Steven Klein, an addiction medicine fellow at the Caron Treatment Centers residential treatment facility in Pennsylvania, prescribes these drugs to patients for this dual purpose

But medication can only do so much and exercise is a no-brainer for enhancing these benefits

Myers in the 1960's

Citation1 This dual burden not only impairs physical performance and quality of life but also increases the risk of falls, frailty, and mortality

Future success will depend on far more than weight-loss efficacy

Care is adjusted over time rather than following a fixed schedule